Endothelial dysfunction and stomach cancer: from knowledge to action
https://doi.org/10.52888/0514-2515-2025-366-3-112-120
Abstract
Gastric cancer (GC) remains one of the most prevalent malignancies worldwide, with a high mortality rate. Among the many pathophysiological mechanisms involved, endothelial dysfunction (ED) has recently been identified as a key factor in tumour progression, angiogenesis, and postoperative complications. This review summarises the current knowledge regarding the role of ED in the pathogenesis of GC, including its impact on the tumour microenvironment, inflammatory processes, metabolic reprogramming and resistance to therapy. Particular attention is paid to molecular markers of ED, such as nitric oxide (NO), von Willebrand factor (vWF) and circulating endothelial cells (CECs), and their prognostic and diagnostic significance. The impact of surgical intervention and chemotherapy on endothelial integrity is also considered. Additionally, the interrelationship between Helicobacter pylori infection, chronic inflammation, and ED is explored. We believe that targeting ED therapeutically may represent a promising approach to improving outcomes in patients with GC.
About the Authors
S. T. Olzhaev
Almaty regional multidisciplinary clinic
Kazakhstan
Competing Interests:
Kazakhstan
Olzhayev Sayakhat Taurbekovich – candidate of medical sciences, associate professor, associate professor of the department of oncology with a course in radiology
Almaty
Competing Interests:
authors declare no conflict of interest
K. S. Titov
Peoples’ Friendship University of Russia named after Patrice Lumumba
Russian Federation
Competing Interests:
Russian Federation
Titov Konstantin Sergeevich – doctor of medical sciences, professor, leading researcher, Moscow multidisciplinary scientific and clinical center named after S.P. Botkin, professor of the department of oncology and roentgenology named after V.P. Kharchenko, Medical institute
Moscow
Competing Interests:
authors declare no conflict of interest
Z. Kh. Huseinzoda
SEI Avicenna Tajik State University
Tajikistan
Competing Interests:
Tajikistan
Huseinzoda Zafar Habibullo – doctor of medical sciences, professor, director of the Republican oncology research center, vice-rector for medical work and postgraduate education
Dushanbe
Competing Interests:
authors declare no conflict of interest
B. Zh. Adzhibayev
Almaty regional multidisciplinary clinic
Kazakhstan
Competing Interests:
Kazakhstan
Adjibayev Baurzhan Zhorkaevich - candidate of medical sciences, assistant professor of the department of internal medicine
Almaty
Competing Interests:
authors declare no conflict of interest
References
1. Zhang X., Yang L., Liu S., Cao L.L., Wang N., Li H.C. et al. [Interpretation on the report of global cancer statistics 2022]. Zhonghua Zhong Liu Za Zhi. 2024, Jul 23;46(7):710-721. Chinese. doi: 10.3760/cma.j.cn112152-20240416-00152.
2. Crusz S.M., Balkwill F.R. Inflammation and cancer: advances and new agents. Nat Rev Clin Oncol. 2015;12(10):584-96. doi: 10.1038/nrclinonc.2015.105.
3. Naderi-Meshkin H., Setyaningsih W.A.W. Endothelial Cell Dysfunction: Onset, Progression and Consequences. Front Biosci (Landmark Ed). 2024 Jun 20;29(6):223. doi: 10.31083/j.fbl2906223.
4. Krogh A. The number and distribution of capillaries in muscles with calculations of the oxygen pressure head necessary for supplying the tissue. J Physiol. 1919 May 20;52(6):409-15. doi: 10.1113/jphysiol.1919.sp001839.
5. Moncada S., Higgs E.A., Vane J.R. Human arterial and venous tissues generate prostacyclin (prostaglandin x), a potent inhibitor of platelet aggregation. Lancet. 1977 Jan 1;1(8001):18-20. doi: 10.1016/s0140-6736(77)91655-5.
6. Lubrano V., Balzan S. Roles of LOX-1 in microvascular dysfunction. Microvasc Res. 2016 May;105:132-40. doi: 10.1016/j.mvr.2016.02.006.
7. Krüger-Genge A., Blocki A., Franke R.P., Jung F. Vascular Endothelial Cell Biology: An Update. Int J Mol Sci. 2019 Sep 7;20(18):4411. doi: 10.3390/ijms20184411.
8. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971 Nov 18;285(21):1182- 6. doi: 10.1056/NEJM197111182852108.
9. Eelen G., de Zeeuw P., Treps L., Harjes U., Wong B.W., Carmeliet P. Endothelial Cell Metabolism. Physiol Rev. 2018 Jan 1;98(1):3-58. doi: 10.1152/physrev.00001.2017.
10. Feldman L. Hypoxia within the glioblastoma tumor microenvironment: a master saboteur of novel treatments. Front Immunol. 2024 Jun 26;15:1384249. doi: 10.3389/fimmu.2024.1384249.
11. Warburg O., Posener K., Negelein E. Über den Stoffwechsel der Tumoren (On metabolism of tumors) Biochem Z. 1924;152:319–344.
12. Warburg O. On the origin of cancer cells. Science. 1956 Feb 24;123(3191):309-14. doi: 10.1126/science.123.3191.309.
13. Walenta S., Voelxen N.F., Mueller-Klieser W. LactateAn Integrative Mirror of Cancer Metabolism. Recent Results Cancer Res. 2016;207:23-37. doi: 10.1007/978-3-319-42118-6_2.
14. Schaaf M.B., Garg A.D., Agostinis P. Defining the role of the tumor vasculature in antitumor immunity and immunotherapy. Cell Death Dis. 2018 Jan 25;9(2):115. doi: 10.1038/s41419-017-0061-0.
15. Yang F., Lee G., Fan Y. Navigating tumor angiogenesis: therapeutic perspectives and myeloid cell regulation mechanism. Angiogenesis. 2024 Aug;27(3):333-349. doi: 10.1007/s10456-024-09913-z/.
16. Leone P., Malerba E., Susca N., Favoino E., Perosa F., Brunori G. et al. Endothelial cells in tumor microenvironment: insights and perspectives. Front Immunol. 2024 Feb 15;15:1367875. doi: 10.3389/fimmu.2024.1367875.
17. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med. 1986 Dec 25;315(26):1650-9. doi: 10.1056/NEJM198612253152606.
18. Malhab L.J.B., Saber-Ayad M.M., Al-Hakm R., Nair V.A., Paliogiannis P., Pintus G. et al. Chronic Inflammation and Cancer: The Role of Endothelial Dysfunction and Vascular Inflammation. Curr Pharm Des. 2021;27(18):2156-2169. doi: 10.2174/1381612827666210303143442.
19. Marcu R., Choi Y.J., Xue J., Fortin C.L., Wang Y., Nagao R.J. et al. Human Organ-Specific Endothelial Cell Heterogeneity. iScience. 2018 Jun 29;4:20-35. doi: 10.1016/j.isci.2018.05.003.
20. Gimbrone, M.A., García-Cardeña G. Endothelial Cell: Dysfunction and the Pathobiology of Atherosclerosis. Circ Res. 2016 Feb 19;118(4):620-36. doi: 1010.1161/CIRCRESAHA.115.306301.
21. Naderi-Meshkin H., Setyaningsih W.A.W. Endothelial Cell Dysfunction: Onset, Progression, and Consequences. Front Biosci (Landmark Ed). 2024 Jun 20;29(6):223. doi: 10.31083/j.fbl2906223.
22. Corban M.T., Lerman L.O., Lerman A. Endothelial Dysfunction. Arterioscler Thromb Vasc Biol. 2019 Jul;39(7):1272-1274. doi: 10.1161/ATVBAHA.119.312836.
23. Theofilis P., Sagris M., Oikonomou E., Antonopoulos A.S., Siasos G., Tsioufis C., Tousoulis D. Inflammatory Mechanisms Contributing to Endothelial Dysfunction. Biomedicines. 2021 Jul 6;9(7):781. doi: 10.3390/biomedicines9070781.
24. Bischoff J. Endothelial-to-Mesenchymal Transition. Circ Res. 2019 Apr 12;124(8):1163-1165. doi: 10.1161/CIRCRESAHA.119.314813.
25. Cho J.G., Lee A., Chang W. et al. Endothelial to Mesenchymal Transition Represents a Key Link in the Interaction between Inflammation and Endothelial Dysfunction. Front Immunol. 2018 Feb 20;9:294. doi: 10.3389/fimmu.2018.00294.
26. Bellien J., Iacob M., Richard V., Wils J., Le CamDuchez V., Joannidès R. Evidence for wall shear stress-dependent t-PA release in human conduit arteries: role of endothelial factors and impact of high blood pressure. Hypertens Res. 2021 Mar;44(3):310-317. doi: 10.1038/s41440-020-00554-5.
27. Resnick N., Gimbrone M.A. Jr. Hemodynamic forces are complex regulators of endothelial gene expression. FASEB J. 1995 Jul;9(10):874-82. doi: 10.1096/fasebj.9.10.7615157.
28. Xiao Z., Zhang Z., Ranjan V., Diamond S.L. Shear stress induction of the endothelial nitric oxide synthase gene is calcium-dependent but not calciumactivated. J Cell Physiol. 1997 May;171(2):205-11. doi: 10.1002/(SICI)1097-4652(199705)171:2<205:AIDJCP11>3.0.CO;2-C.
29. Katayama Y., Uchino J., Chihara Y. et al. Tumor Neovascularization and Developments in Therapeutics. Cancers (Basel). 2019 Mar 6;11(3):316. doi: 10.3390/cancers11030316.
30. Dudvarski Stanković N., Bicker F., Keller S. et al. EGFL7 enhances surface expression of integrin α5β1 to promote angiogenesis in malignant brain tumors. EMBO Mol Med. 2018 Sep;10(9):e8420. doi: 10.15252/emmm.201708420.
31. Melincovici C.S., Boşca A.B., Şuşman S. et al. Vascular endothelial growth factor (VEGF) - key factor in normal and pathological angiogenesis // Rom J Morphol Embryol. 2018;59(2):455-467. PMID: 30173249.
32. Lugano R., Ramachandran M., Dimberg A. Tumor angiogenesis: causes, consequences, challenges and opportunities. Cell Mol Life Sci. 2020 May;77(9):1745- 1770. doi: 10.1007/s00018-019-03351-7.
33. Chennakrishnaiah S., Tsering T., Gregory C., Tawil N., Spinelli C., Montermini L. et al. Extracellular vesicles from genetically unstable, oncogene-driven cancer cells trigger micronuclei formation in endothelial cells. Sci Rep. 2020 May 22;10(1):8532. doi: 10.1038/s41598-020-65640-7.
34. Chiarella P., Capone P., Sisto R. Contribution of Genetic Polymorphisms in Human Health. Int J Environ Res Public Health. 2023 Jan 4;20(2):912. doi: 10.3390/ijerph20020912.
35. Feng Y., Luo S., Fan D. et al. The role of vascular endothelial cells in tumor metastasis / Y. Feng, // Acta Histochem. 2023 Aug;125(6):152070. doi: 10.1016/j.acthis.2023.152070.
36. Vasina L.V., Petrishchev N.N., Vlasov T.D. Endothelial dysfunction and its main markers. Regional Blood Circulation and Microcirculation. 2017;16(1):4–15. (In Russ.). DOI: 10.24884/1682-6655-2017-16-1-4-15.
37. Patmore S., Dhami S.P.S., O’Sullivan J.M. Von Willebrand factor and cancer; metastasis and coagulopathies. J Thromb Haemost 2020 Oct;18(10):2444-2456. doi: 10.1111/jth.14976.
38. Moik F., Ay C. Hemostasis and cancer: Impact of haemostatic biomarkers for the prediction of clinical outcomes in patients with cancer. J Thromb Haemost 2022 Dec;20(12):2733-2745. doi: 10.1111/jth.15880.
39. Petrishchev N.N., Berkovich O.A., Vlasov T.D. et al. Diagnostic value of determining desquamated endothelial cells in the blood. Clinical Laboratory Diagnostics. 2001;(1):50–52. (In Russ.).
40. Stepanova T.V., Ivanov A.N., Tereshkina N.E. et al. Markers of endothelial dysfunction: pathogenetic role and diagnostic significance. Klin Lab Diagn. 2019;64(1):34-41. doi: 10.18821/0869-2084-2018-63-34-41.
41. Baturin V.A., Fischer V.V., Sergeev S.A., Yatsuk I.V. Magnesium-calcium balance and endothelial dysfunction during surgical stress. Medical News of North Caucasus. 2014;9(1):22–25. (In Russ.). DOI: 10.14300/mnnc.2014.09006.
42. Park Y.H., Kim N. Review of atrophic gastritis and intestinal metaplasia as a premalignant lesion of gastric cancer. J Cancer Prev 2015 Mar;20(1):25-40. doi: 10.15430/JCP.2015.20.1.25.
43. Reyes V.E. Helicobacter pylori and Its Role in Gastric Cancer. Microorganisms. 2023 May 17;11(5):1312. doi: 10.3390/microorganisms11051312.
44. Wang M., Cai W., Yang A.J. et al. Gastric cancer cell-derived extracellular vesicles disrupt endothelial integrity and promote metastasis. Cancer Lett. 2022 Oct 1;545:215827. doi: 10.1016/j.canlet.2022.215827.
45. Li B., Nie Z., Zhang D. et al. Roles of circulating endothelial progenitor cells and endothelial cells in gastric carcinoma. Oncol Lett. 2018 Jan;15(1):324-330. doi: 10.3892/ol.2017.7272.
46. Senchukova M.A. Issues of origin, morphology and clinical significance of tumor microvessels in gastric cancer. World J Gastroenterol. 2021 Dec 28;27(48):8262-8282. doi: 10.3748/wjg.v27.i48.8262.
47. Macedo F., Ladeira K., Longatto-Filho A. et al. Gastric Cancer and Angiogenesis: Is VEGF a Useful Biomarker to Assess Progression and Remission? J Gastric Cancer. 2017 Mar;17(1):1-10. doi: 10.5230/jgc.2017.17.e1.
48. Kirichenko Y.Y., Belenkov Y.N., Privalova E.V. et al. Vasculotoxicity of Chemotherapy: Assessment оf Endothelial Dysfunction Biomarkers’ Levels in Gastric Cancer Patients. Kardiologiia. 2020 Jun 2;60(5):1069. doi: 10.18087/cardio.2020.5.n1069.
49. Campia U. Vascular effects of cancer treatments. Vasc Med. 2020 Jun;25(3):226-234. doi: 10.1177/1358863X20914978.
50. Su J.B. Vascular endothelial dysfunction and pharmacological treatment. World J Cardiol. 2015 Nov 26;7(11):719-41. doi: 10.4330/wjc.v7.i11.719.
Review
For citations:
Olzhaev S.T., Titov K.S., Huseinzoda Z.Kh., Adzhibayev B.Zh. Endothelial dysfunction and stomach cancer: from knowledge to action. Health care of Tajikistan. 2025;(3):112-124. (In Russ.) https://doi.org/10.52888/0514-2515-2025-366-3-112-120
Views:
19
Email this article 